In the United States, aflibercept-yszy received Food and Drug Administration (FDA) approval in May 2024 as a biosimilar to Eylea (aflibercept) 2 mg (40 mg/mL).⁴ The newly announced settlement resolves ...

"Emerging wet AMD therapies including Fovista and abicipar pegol (Allergan/Molecular Partners) will need to be priced competitively to Eylea and Lucentis in order to garner favorable tier placement.

Alvotech has moved one step closer to entering the Eylea (aflibercept 2 mg) biosimilar market, after a European Medicines Agency (EMA) panel recommended approval of its copycat biologic. Issued by the ...

TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) ...

Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals (REGN.O), opens new tab on Thursday reported weaker-than-expected quarterly sales of the higher dose version of its blockbuster eye disease ...

Please provide your email address to receive an email when new articles are posted on . The decision is supported by positive visual acuity gains found in the phase 3 QUASAR trial. This is the fourth ...

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea®1 Agreement builds on the proven and successful collaboration of ...

Teva Pharmaceuticals has announced a strategic collaboration with Klinge Biopharma and Formycon for the semi-exclusive commercialization of FYB203, a biosimilar candidate to Eylea® (aflibercept), in ...

Despite a beat on both top and bottom lines with its Q3 2024 financials, Regeneron Pharmaceuticals (NASDAQ:REGN) lost more than 10% on Thursday, a move BMO Capital Markets attributed to ...

TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual ...